Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

BACKGROUND: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with and without liraglutide treatment on...

Descripción completa

Detalles Bibliográficos
Autores principales: Engelbrechtsen, L., Lundgren, J., Wewer Albrechtsen, N. J., Mahendran, Y., Iepsen, E. W., Finocchietto, P., Jonsson, A. E., Madsbad, S., Holst, J. J., Vestergaard, H., Hansen, T., Torekov, S. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729494/
https://www.ncbi.nlm.nih.gov/pubmed/29259801
http://dx.doi.org/10.1002/osp4.133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729494/
https://www.ncbi.nlm.nih.gov/pubmed/29259801
http://dx.doi.org/10.1002/osp4.133

Ejemplares similares